Legence Corp. (NASDAQ: LGN) announced that Blackstone‑affiliated shareholders will offer and sell 11 million shares of the company’s Class A common stock in a secondary underwritten public offering. The sale is being conducted by the selling shareholders; Legence will not receive any proceeds and will bear only the underwriting costs. The offering includes a 30‑day option for the underwriters to purchase an additional 1.65 million shares on the same terms.
The Form S‑1 registration statement for the offering was filed on April 6 2026 and has not yet become effective. The shares will be sold only after the registration becomes effective. Goldman Sachs, Jefferies, and Bank of America serve as joint lead book‑running managers, with Blackstone Capital Markets as co‑manager.
Legence’s 2025 financial results provide context for the secondary sale. The company reported revenue of $2,550.5 million, a net loss of $77.3 million, and adjusted EBITDA of $298.8 million, while its backlog of contracts stood at $3.7 billion. The company’s business focuses on engineering, consulting, installation, and maintenance of mission‑critical systems in buildings, with a client base that includes more than 60 % of Nasdaq‑100 companies and strong exposure to data‑center, technology, life‑science, and healthcare sectors.
Previous secondary offerings by Blackstone‑affiliated holders in December 2025—7 million shares on December 9 and 8.4 million shares on December 11—were followed by notable declines in Legence’s share price. The pattern suggests that investors view these sales as a signal of insider cash‑out and potential dilution, and the current offering may elicit a similar market reaction.
The secondary offering does not provide Legence with additional capital, but it reflects Blackstone’s strategy to monetize its investment. The increased share count will dilute earnings per share, yet the company’s management has not issued new commentary. Legence continues to pursue growth in its core segments, supported by a robust backlog and a focus on high‑growth markets such as data centers and life sciences.
The secondary offering is a significant capital‑market event that will affect Legence’s share count and liquidity profile, but it does not alter the company’s operational trajectory or strategic focus.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.